Phio's Skin Cancer Therapy Shows 85% Response, Gains B2i Digital Spotlight
February 23, 2026 — Phio Pharmaceuticals reports 85% response in Phase 1b skin cancer trial with PH-762, no serious adverse events. FDA submission targeted for 2026, cash extends to 2027. Selected as B2i Digital Featured Company.